Sagimet Doses First Patient in U.S. Phase III Denifanstat Acne Trial
Sagimet said the U.S. trial is for moderate to severe acne. The study is designed to enroll approximately…
Story updates
12:10:51 AM UTC
SquawkNews
Ascletis said partner Sagimet dosed the first patient in AURORA, a pivotal U.S. Phase III trial of denifanstat (ASC40) for moderate to severe acne, targeting about 800 patients including ~450 adolescents.Material DetailsContext by AI AnalystThis is an early U.S. registrational step building on Chin…